Thioredoxin-Interacting Protein as a Novel Potential Therapeutic Target in Diabetes Mellitus and Its Underlying Complications
Dawit Zewdu Wondafrash,1 Asmelash Tesfay Nire’a,2 Gebrehiwot Gebremedihn Tafere,1 Desilu Mahari Desta,3 Demoze Asmerom Berhe,4 Kaleab Alemayehu Zewdie1 1Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia; 2Pharmacology and Toxicology Resear...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-01-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Subjects: | |
| Online Access: | https://www.dovepress.com/thioredoxin-interacting-protein-as-a-novel-potential-therapeutic-targe-peer-reviewed-article-DMSO |
| _version_ | 1811173764919984128 |
|---|---|
| author | Wondafrash DZ Nire'a AT Tafere GG Desta DM Berhe DA Zewdie KA |
| author_facet | Wondafrash DZ Nire'a AT Tafere GG Desta DM Berhe DA Zewdie KA |
| author_sort | Wondafrash DZ |
| collection | DOAJ |
| description | Dawit Zewdu Wondafrash,1 Asmelash Tesfay Nire’a,2 Gebrehiwot Gebremedihn Tafere,1 Desilu Mahari Desta,3 Demoze Asmerom Berhe,4 Kaleab Alemayehu Zewdie1 1Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia; 2Pharmacology and Toxicology Research and Course Unit, Department of Pharmacy, Axum University, Axum, Ethiopia; 3Clinical Pharmacy Research and Course Unit, School of Pharmacy, Mekelle University, Mekelle, Ethiopia; 4Department of Medicinal Chemistry, School of Pharmacy, Mekelle University, Mekelle, EthiopiaCorrespondence: Dawit Zewdu WondafrashDepartment of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, P.O. Box: 1871, Mekelle, EthiopiaTel +251910127356Email davaniye@gmail.comAbstract: Diabetes mellitus (DM) is a common metabolic disorder which is characterized by a persistent increment of blood glucose. Globally, DM affects millions of people and the prevalence is increasing alarmingly. The critical step in the pathophysiology of DM is the loss of β-cells of the pancreas, which are responsible for the secretion of insulin. Thioredoxin-interacting protein (TXNIP) is among the factors that control the production and loss of the pancreatic β-cells. TXNIP is an α-arrestin that can bind and inhibit thioredoxin (the antioxidant protein) which is produced in the pancreatic islet after glucose intake. Numerous studies illustrated that elevated TXNIP levels were found to induce β-cell apoptosis; whereas TXNIP deficiency protects against type I and type II diabetes by promoting β-cell survival. Nowadays, TXNIP depletion is becoming a key factor in pancreatic β-cell survival enhancement. In the present review, targeting TXNIP is found to be relevant as a unique therapeutic opportunity, not only to improve insulin secretion and sensitivity, but also ameliorating the long term microvascular and macrovascular complications of the disease. Thus, TXNIP inhibitors that could reduce the expression and/or activity of TXNIP to non-diabetic levels are promising agents to halt the alarming rate of diabetes and its related complications.Keywords: diabetes mellitus, thioredoxin, TXNIP, TXNIP modulators, verapamil |
| first_indexed | 2024-04-10T17:53:28Z |
| format | Article |
| id | doaj.art-e120ff783cf64328b3bfcada75f0a2d6 |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-04-10T17:53:28Z |
| publishDate | 2020-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-e120ff783cf64328b3bfcada75f0a2d62023-02-02T20:01:41ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072020-01-01Volume 13435150917Thioredoxin-Interacting Protein as a Novel Potential Therapeutic Target in Diabetes Mellitus and Its Underlying ComplicationsWondafrash DZNire'a ATTafere GGDesta DMBerhe DAZewdie KADawit Zewdu Wondafrash,1 Asmelash Tesfay Nire’a,2 Gebrehiwot Gebremedihn Tafere,1 Desilu Mahari Desta,3 Demoze Asmerom Berhe,4 Kaleab Alemayehu Zewdie1 1Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, Ethiopia; 2Pharmacology and Toxicology Research and Course Unit, Department of Pharmacy, Axum University, Axum, Ethiopia; 3Clinical Pharmacy Research and Course Unit, School of Pharmacy, Mekelle University, Mekelle, Ethiopia; 4Department of Medicinal Chemistry, School of Pharmacy, Mekelle University, Mekelle, EthiopiaCorrespondence: Dawit Zewdu WondafrashDepartment of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, P.O. Box: 1871, Mekelle, EthiopiaTel +251910127356Email davaniye@gmail.comAbstract: Diabetes mellitus (DM) is a common metabolic disorder which is characterized by a persistent increment of blood glucose. Globally, DM affects millions of people and the prevalence is increasing alarmingly. The critical step in the pathophysiology of DM is the loss of β-cells of the pancreas, which are responsible for the secretion of insulin. Thioredoxin-interacting protein (TXNIP) is among the factors that control the production and loss of the pancreatic β-cells. TXNIP is an α-arrestin that can bind and inhibit thioredoxin (the antioxidant protein) which is produced in the pancreatic islet after glucose intake. Numerous studies illustrated that elevated TXNIP levels were found to induce β-cell apoptosis; whereas TXNIP deficiency protects against type I and type II diabetes by promoting β-cell survival. Nowadays, TXNIP depletion is becoming a key factor in pancreatic β-cell survival enhancement. In the present review, targeting TXNIP is found to be relevant as a unique therapeutic opportunity, not only to improve insulin secretion and sensitivity, but also ameliorating the long term microvascular and macrovascular complications of the disease. Thus, TXNIP inhibitors that could reduce the expression and/or activity of TXNIP to non-diabetic levels are promising agents to halt the alarming rate of diabetes and its related complications.Keywords: diabetes mellitus, thioredoxin, TXNIP, TXNIP modulators, verapamilhttps://www.dovepress.com/thioredoxin-interacting-protein-as-a-novel-potential-therapeutic-targe-peer-reviewed-article-DMSOdiabetes mellitusthioredoxintxniptxnip modulatorsverapamil |
| spellingShingle | Wondafrash DZ Nire'a AT Tafere GG Desta DM Berhe DA Zewdie KA Thioredoxin-Interacting Protein as a Novel Potential Therapeutic Target in Diabetes Mellitus and Its Underlying Complications Diabetes, Metabolic Syndrome and Obesity diabetes mellitus thioredoxin txnip txnip modulators verapamil |
| title | Thioredoxin-Interacting Protein as a Novel Potential Therapeutic Target in Diabetes Mellitus and Its Underlying Complications |
| title_full | Thioredoxin-Interacting Protein as a Novel Potential Therapeutic Target in Diabetes Mellitus and Its Underlying Complications |
| title_fullStr | Thioredoxin-Interacting Protein as a Novel Potential Therapeutic Target in Diabetes Mellitus and Its Underlying Complications |
| title_full_unstemmed | Thioredoxin-Interacting Protein as a Novel Potential Therapeutic Target in Diabetes Mellitus and Its Underlying Complications |
| title_short | Thioredoxin-Interacting Protein as a Novel Potential Therapeutic Target in Diabetes Mellitus and Its Underlying Complications |
| title_sort | thioredoxin interacting protein as a novel potential therapeutic target in diabetes mellitus and its underlying complications |
| topic | diabetes mellitus thioredoxin txnip txnip modulators verapamil |
| url | https://www.dovepress.com/thioredoxin-interacting-protein-as-a-novel-potential-therapeutic-targe-peer-reviewed-article-DMSO |
| work_keys_str_mv | AT wondafrashdz thioredoxininteractingproteinasanovelpotentialtherapeutictargetindiabetesmellitusanditsunderlyingcomplications AT nireaat thioredoxininteractingproteinasanovelpotentialtherapeutictargetindiabetesmellitusanditsunderlyingcomplications AT taferegg thioredoxininteractingproteinasanovelpotentialtherapeutictargetindiabetesmellitusanditsunderlyingcomplications AT destadm thioredoxininteractingproteinasanovelpotentialtherapeutictargetindiabetesmellitusanditsunderlyingcomplications AT berheda thioredoxininteractingproteinasanovelpotentialtherapeutictargetindiabetesmellitusanditsunderlyingcomplications AT zewdieka thioredoxininteractingproteinasanovelpotentialtherapeutictargetindiabetesmellitusanditsunderlyingcomplications |